Management Team

David Levison

Steven Rosenberg, Ph.D.

Mark Monane, M.D.

Andrew Guggenhime

Deborah L. Kilpatrick, Ph.D.

Mark R. Willig

Susan Daniels, Ph. D.

Erwin Estigarribia

Gwen Carscadden



David Levison | President and CEO
David Levison


David Levison is the Founder, Chief Executive Officer, and Director of CardioDx. Prior to launching CardioDx, David was a Venture Partner at Texas Pacific Group Ventures and was also the interim Chief Executive Officer of XDx, Inc., a molecular diagnostic company focused on the immune system. Previously, he was the Founder, President and Chief Executive Officer of iScribe, a healthcare technology company acquired by AdvancePCS (now Caremark) in December 2001. Prior to iScribe, David was President of Oncology Therapeutics Network (OTN), which was acquired by Bristol-Myers Squibb in 1996. David also served as Chief Financial Officer of OTN's parent company, Axion, from 1990 to 1993. Prior to Axion, he was with Cole Gilburne Fund, an early-stage, technology-focused venture capital firm. David received his M.B.A. from Stanford University and his B.S. from Williams College.

top arrow

 

Steven Rosenberg, Ph.D. | Consulting Chief Scientific Officer
Steve Rosenberg


Steven Rosenberg joined CardioDx in 2006 and is responsible for the scientific staff and for research and development programs in the areas of genomics, genetics, and informatics. In addition, Steven is currently on the Board of Directors of KMT Hepatech. Prior to joining CardioDx, Steven served for three years as the Chief Scientific Officer of XDx, Inc., a molecular diagnostics company focused on the immune system. He led the group responsible for developing AlloMap, a molecular diagnostic for heart transplant patients, the first genomics-based test in transplant immunology. Prior to XDx, Steven spent a year as a consultant and visiting scholar at the University of California, Berkeley. From 1981 to 2001 he was at Chiron Corporation, where he was named one of only three Chiron Research Fellows in the company's history. He received his Ph.D. in biochemistry from the University of California, Berkeley, and is the author of more than 40 scientific publications, and an inventor of more than 20 U.S. patents.

top arrow

 

Mark Monane, M.D. | Chief Medical Officer
Mark Monane

Mark Monane joined CardioDx in 2011 as Chief Medical Officer. Prior to joining CardioDx, he served 11 years as managing director of equity research for Needham & Company, where he focused on analyses of emerging biotechnology companies in the cardiovascular and cancer disease areas. Prior to Needham & Company, Mark served as Senior Director of Medical Policy and Practices at Medco Health. Before joining Medco, he was an assistant professor at Harvard Medical School and the Harvard School of Public Health, where he completed fellowship training in geriatrics, clinical pharmacology, and clinical effectiveness. Mark holds an A.B. and an M.B.A. from Columbia University, an M.S. degree in health policy from Harvard University, and an M.D. from New York University.

top arrow




Andrew Guggenhime | Chief Financial Officer
Andrew Guggenhime

Andrew Guggenhime joined CardioDx in 2011 as Chief Financial Officer. Andrew has more than 11 years of CFO experience, including more than nine years as CFO of a public company. Most recently, he served as CFO for Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company acquired in April 2011 by Gilead Sciences. Prior to Calistoga Pharmaceuticals, Andrew served as Senior Vice President and Chief Financial Officer for Facet Biotech Corporation, a publicly-held company acquired in April 2010 by Abbott Laboratories. He also served as CFO for PDL BioPharma, Inc., a publicly-held biopharmaceutical company, and Neoforma, Inc., a provider of supply-chain management solutions for the healthcare industry. Andrew began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He holds a B.A. from Middlebury College, and an M.M. from the J.L. Kellogg Graduate School of Management at Northwestern University.

top arrow




Deborah L. Kilpatrick, Ph.D. | Chief Commercial Officer
Deborah Kilpatrick


Deborah Kilpatrick joined CardioDx in 2006 as Vice President, Market Development, with responsibility for building the marketing and reimbursement capabilities of the company. She currently oversees commercial functions that include provider marketing and sales, managed care marketing and sales, market access, and public relations. Prior to joining CardioDx, she spent nine years at the Vascular Intervention Division of Guidant Corporation where her roles included Research Fellow, Director of Research and Technology Development, and Director of New Ventures. Deborah serves on the Advisory Boards for the Georgia Institute of Technology and its College of Engineering. She is on the Board of Directors for the Dystonia Medical Research Foundation and is a Fellow of the American Institute of Medical and Biological Engineering. Deborah is a founder of the annual MedtechVision Conference in Silicon Valley and has received a Rising Star award from the Healthcare Businesswoman's Association. She holds multiple U.S. patents and a Ph.D. in mechanical engineering with a focus in cardiovascular bioengineering from the Georgia Institute of Technology.

top arrow

 

Mark R. Willig | Senior Vice President, Sales
Mark R. Willig


Mark joined CardioDx in 2013 as Senior Vice President of Sales with responsibility for provider and managed care sales, sales operations, and market access. Prior to joining CardioDx, Mark was Executive Vice President of Global Sales at Agendia. Mark has held several sales and marketing leadership roles including Vice President of Global Sales with Thermo Fisher Scientific and Executive Vice President of Sales and Marketing at Specialty Laboratories. He was also the first Vice President of Sales at Myriad Genetic Laboratories. Early in his career, Mark spent more than a decade in several sales and sales management roles at Abbott Diagnostics, and he holds a B.A. in Communications from the University of Missouri.

top arrow

 

Susan Daniels, Ph.D. | Vice President, Development
Susan Daniels


Susan Daniels joined CardioDx in 2004, and is responsible for the development of the company's genomic testing products. She has more than 17 years of experience in the genomics industry. Prior to CardioDx, Susan served as Vice President of Curation Sciences at Incyte, where she was responsible for managing the development of genomic-information products. In that role, she managed several multimillion-dollar drug discovery and target validation collaborations with pharmaceutical companies. Prior to joining Incyte, Susan was a Senior Scientist at Axys Pharmaceuticals (formerly Sequana Therapeutics), where she managed projects focused on mapping genes linked to complex inflammatory disorders. Her postdoctoral research was carried out at the Wellcome Trust Centre for Human Genetics at Oxford University. There she completed a genome-wide linkage analysis study that led to the identification of a number of genes associated with asthma. Susan received her Ph.D. in biochemistry from the University of Wales, Cardiff, in the United Kingdom.

top arrow

 

Erwin Estigarribia | Vice President, Operations
Erwin Estigarribia


Erwin joined CardioDx in 2013 as Vice President of Operations with responsibility for facilities and logistics, customer service and reimbursement, CLIA commercial laboratory, and information technology. Prior to joining CardioDx, Erwin was Vice President of Manufacturing and Quality Operations at NuGEN Technologies, a global provider of complex sample preparation solutions for early research and molecular diagnostic companies. Before NuGEN, Erwin served as Senior Director of Manufacturing Sciences for Geron Corporation, working on novel processes including cellular therapies and devices. He also served as Associate Director of process development for Novartis Vaccines and Diagnostics (formerly Chiron), working on HIV and HCV product families under ISO 13485 and cGMP processes. Prior to Novartis, Erwin held bioprocess consulting engineering positions with PoroCrit, Sims SFE LLC, and Commonwealth Serum Laboratories. Erwin received a bachelor of chemical and bioprocess engineering with honors from Swinburne University of Technology, Melbourne, Australia.

top arrow

 

Gwen Carscadden | Vice President, Human Resources
Gwen Carscadden


Gwen Carscadden joined CardioDx in 2012 as Vice President, Human Resources. She has more than 25 years of human resources experience, with various roles of increasing scope and responsibility. Most recently, she provided executive level human resources consulting services to CardioDx and two Bay Area biotechnology companies. Prior to that, she served as Vice President, Human Resources for Facet Biotech, which was acquired by Abbott Laboratories. Gwen previously served as Executive Director of Human Resources for PDL Biopharma. She began her career in the high-tech sector, working for Amdahl Corporation and Fujitsu Computer Systems. Gwen holds an M.A. in organizational communication from San Jose State University, and a B.A. in behavioral sciences also from San Jose State.

top arrow